Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00120523
Status:
COMPLETED
Last Update Posted:
2022-02-11
First Post:
2005-07-11
Brief Title:
5-Year Safety Study of Pimecrolimus Cream 1 in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis
Sponsor:
MEDA Pharma GmbH Co KG
Organization:
Viatris Inc
Study Overview
Official Title:
Five-Year Safety Study of Pimecrolimus Cream 1 in Infants 3 to Less Than 12 Months of Age With Mild to Moderate Atopic Dermatitis
Status:
COMPLETED
Status Verified Date:
2016-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to investigate the safety of pimecrolimus cream 1 in the long-term treatment up to 5 years of atopic dermatitis eczema in patients less than 12 months of age compared to topical corticosteroids TCS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None